Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan · Delayed Price · Currency is TWD 97.10
-0.40 (-0.41%)
Nov 3, 2025, 1:30 PM CST
Gongwin Biopharm Holdings Company Description
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs.
It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.
The company was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co., Ltd.
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mao Yuan Lin |
Contact Details
Address: No. 80, Jianguo North Road Taipei, 104 Taiwan | |
| Phone | 886 2 2503 5282 |
| Website | gongwinbiopharm.com |
Stock Details
| Ticker Symbol | 6617 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG409471060 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chonghan Wu Ph.D. | Founder and Chairman |
| Mao Yuan Lin | GM and Director |
| Rocky Shih | Co-Founder |
| Nan Hu Wei | Chief Financial Officer and Head of Administration Division |